What Is RGCC Testing

Over the past 10 years, RGCC exams have emerged to be one of the most accurate and complete diagnoses via liquid biopsy.

RGCC uses only a single blood sample for all cancers (solid tumors, blood, sarcomas, etc.), except for the brain and primary tumors of the Central Nervous System (glioblastoma, astrocytoma, meningioma, etc.). an invasive tissue biopsy is required for this test.

At this stage, it is noteworthy that the analyzes of RGCC are focused on stopping both Circulating Tumor Cells ( CTCs) and Cancer Stem Cells (CSC) to cause metastatic tumors that are responsible for at least 90% of all cancer-related deaths.

CTCs and CSCs possess all the information and capabilities of forming microcolonizations, often becoming potent micrometastases. That is why cancer recurrence occurs. For this reason RGCC has selected a blood sample as the most suitable medium for analysis, since it includes the CTCs with the most pertinent information for the calculation of risk for both a potent metastasis and / or a new occurrence from months to years.

Why do we recommend RGCC ?

Over the last 12 years, RGCC exams have emerged to be one of the most accurate and complete tests in Liquid Biopsy, which has been seen to date. The test is conducted in Greece by Dr. Ioannis Papasotiriou, MD, PhD, scientific director of RGGC Ltd. and has been perfected over the years. With the use of a simple blood sample, RGCC can work with all types of cancer (solid tumors, blood cancer, sarcomas, etc.) except brain and primary tumors of the nervous system.

The field of oncology has become highly competitive over the past 4-5 years due to an early paradigm shift, based on a huge lack of predictable good results. Large international cancer centers have begun to develop similar tests in the past 4 years, estimating that they could begin to be used in about 5 to 10 years. At this point, none of these centers or any others that have managed to reach the accuracy that the RGCC Lab of Greece make from only 15-20ml of blood.

We know that cancer is metastasizing [spreading] in most cancer patients for many, many years with few perceptual changes. Until recently, no one knew for certain how or why this happened, very often. Now many scientists around the world are finding out that it is due to Tumor Trunk Cells and Circulating Tumor Cells (CSCs / CTCs).

This is fast becoming the focus of many cancer research, in which it aims to stop CSCs and CTCs from causing metastatic tumors that account for at least 90% of all cancer-related deaths. In addition, many scientists suspect that CTCs and CSCs are the cause of almost or all of the metastases that occur. With this new information, circulating CTCs and CSCs are becoming the primary target of oncologists.

The cancer tumor is bad enough, but it's the CSCs and CTCs that are the real problem. These cells are responsible for the metastasis and return of this chronic and systemic disease. Over the past 42 years, trillions of dollars have been spent on cancer research and treatments since the war on cancer was declared in 1971. The overall results of these efforts, time and money, result in only increasing the survival rate of 2 , 1 to 7.5% in 5 years. All this time, money spent, suffering and death of patients, is not something that would be a source of pride and definitely not a good return on the billions or trillions of dollars that were invested.

Who are these exams for?

Patients with

Early Stage Cancer

Patients in

Generalized Advanced Stage

Rare or

Unknown Origin Cancers

Tumors With Difficulty of

Access Through Traditional Biopsy

Patients Who Do Not Respond to

Conventional Treatments

Insufficient Information Obtained by

Traditional Biopsy

  1. What if it was possible for you to detect cancer earlier?
  2. What if you could drastically improve your patient outcome?
  3. What if there is another way to ensure the best possible treatment for your patients?


What is the most comprehensive text?

ONCONOMICS PLUS , which covers the sensitivity / resistance to cytotoxic drugs and natural biological substances and CHEMOSNIP, which covers the ability of patients to activate and metabolise drugs properly.

Can a patient include additional substances in any of their tests?

Yes, R.G.C.C. can test other natural substances requested by the patient in the Onconomics Plus or Onconomics Extracts tests. If additional tests are required for chemotherapy drugs, we may include them in the Onconomics or Onconomics Plus test.

How long should I wait to get the results?

Usually the results are available within 10 to 14 days from the exam collection date.

How long is it recommended to perform a monitoring / follow-up test?

From 3 to 6 months after the treatment plan.

Why in tissue samples are the numbers of CTCs not indicated?

Since the biopsy is already part of the tumor, it means that all the cells are cancerous. For this reason, there is no need to look for CTC populations.

Is blood sample as good as a tissue sample? What are the limitations of using blood?

The main cells of interest in the analytical platform are the CTCs, which are obtained by negative selection and screening via the flow cytometer (so that we obtain only the viable CTCs from a blood sample). In cases such as Glioblastoma, cancer cells can not be detected in a blood sample because of the blood-brain barrier and we need a tissue sample in order to proceed with the test.

How many cancer-specific cells are being tested for one type of cancer?

In one type of cancer for several cancer cell subpopulations, but only one has the properties tumor early (known as Cancer Stem Cells and Cancer Stem Cells ). The subset of the remainder does not actually promote the progression of the disease. Therefore, this is the population that was interested in collecting and analyzing and this subset exists to a greater extent in CTCs.

What can be evaluated with RGCC LIQUID BIOPSY?


Request More Information

Circulating Tumor Cells

Circulating Tumor Cells: An Important Breakthrough in Cancer Treatment!

Cancer Stem Cell:

A Little Known Truth About Cancer Recurrence


Sensitivity / Resistance tests that aid in Personalization and Treatment Effectiveness

RGCC Molecular Profiles

Onco Trace RGCC

Profile of Detection, Count and Monitoring of Circulating Tumor Cells (CTC's) and Cancer Stem Cells (CSC'S). It also serves as a Preventive Measure..

Onconomics Plus

RECOMMENDED! Customized profile that determines the most effective individualized treatment including cytotoxic drugs and natural substances.


Profile that provides information on each individual's ability to metabolize and activate each therapeutic agent in its effective form.

Dr Ioannis Papasotiriou




Other Physician Testimonies

What is CTC